Copanlisib | hsa00040 | Pentose and glucuronate interconversions | 4.00E-02 | 1 | P15121 | AKR1B1 | More | |
Copanlisib | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
Copanlisib | hsa00500 | Starch and sucrose metabolism | 6.17E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
Copanlisib | hsa00600 | Sphingolipid metabolism | 2.77E-02 | 3 | Q9BX95, Q8TCT0, P15289 | SGPP1, CERK, ARSA | More | |
Copanlisib | hsa00630 | Glyoxylate and dicarboxylate metabolism | 5.34E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | |
Copanlisib | hsa00730 | Thiamine metabolism | 2.27E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
Copanlisib | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | |
Copanlisib | hsa00790 | Folate biosynthesis | 2.02E-02 | 1 | P15121 | AKR1B1 | More | |
Copanlisib | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.00E-02 | 1 | P09211 | GSTP1 | More | |
Copanlisib | hsa00983 | Drug metabolism - other enzymes | 1.64E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | |
Copanlisib | hsa01040 | Biosynthesis of unsaturated fatty acids | 2.92E-02 | 2 | P22307, Q9H5J4 | SCP2, ELOVL6 | More | |
Copanlisib | hsa01522 | Endocrine resistance | 4.48E-02 | 4 | P22694, Q02750, Q9UM47, P46527 | PRKACB, MAP2K1, NOTCH3, CDKN1B | More | |
Copanlisib | hsa01524 | Platinum drug resistance | 4.78E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa03010 | Ribosome | 2.25E-04 | 5 | P40429, Q07020, P27635, P05386, P62249 | RPL13A, RPL18, RPL10, RPLP1, RPS16 | More | |
Copanlisib | hsa03040 | Spliceosome | 4.19E-02 | 5 | Q14562, O60508, P08579, Q01130, O43447 | DHX8, CDC40, SNRPB2, SFRS2, PPIH | More | |
Copanlisib | hsa04014 | Ras signaling pathway | 5.91E-03 | 8 | Q02750, P31751, Q15389, P17252, P21359, P0DP23, P62879, P22694 | MAP2K1, AKT2, ANGPT1, PRKCA, NF1, CALM1, GNB2, PRKACB | More | |
Copanlisib | hsa04015 | Rap1 signaling pathway | 6.14E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa04022 | cGMP-PKG signaling pathway | 5.07E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa04024 | cAMP signaling pathway | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa04060 | Cytokine-cytokine receptor interaction | 4.71E-02 | 2 | P78552, O75509 | IL13RA1, TNFRSF21 | More | |
Copanlisib | hsa04066 | HIF-1 signaling pathway | 4.48E-02 | 4 | P17252, Q15389, Q02750, P46527 | PRKCA, ANGPT1, MAP2K1, CDKN1B | More | |
Copanlisib | hsa04072 | Phospholipase D signaling pathway | 9.70E-03 | 2 | Q92529, Q14344 | SHC3, GNA13 | More | |
Copanlisib | hsa04137 | Mitophagy - animal | 1.41E-03 | 3 | P67870, P19532, P18848 | CSNK2B, TFE3, ATF4 | More | |
Copanlisib | hsa04218 | Cellular senescence | 3.65E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa04261 | Adrenergic signaling in cardiomyocytes | 4.57E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa04370 | VEGF signaling pathway | 3.60E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa04371 | Apelin signaling pathway | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa04380 | Osteoclast differentiation | 2.72E-04 | 8 | Q9NQC7, Q9UQC2, Q16539, P31751, P14778, O75015, P01375, Q8N149 | CYLD, GAB2, MAPK14, AKT2, IL1R1, FCGR3B, TNF, LILRA2 | More | |
Copanlisib | hsa04392 | Hippo signaling pathway - multiple species | 3.01E-02 | 1 | Q6V0I7 | FAT4 | More | |
Copanlisib | hsa04540 | Gap junction | 2.03E-02 | 4 | P17252, P22694, P68371, Q02750 | PRKCA, PRKACB, TUBB2C, MAP2K1 | More | |
Copanlisib | hsa04620 | Toll-like receptor signaling pathway | 4.78E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa04622 | RIG-I-like receptor signaling pathway | 1.81E-02 | 1 | Q9NQC7 | CYLD | More | |
Copanlisib | hsa04625 | C-type lectin receptor signaling pathway | 2.27E-04 | 7 | Q9ULY5, Q9NQC7, P20749, P01375, P31751, P0DP23, Q16539 | CLEC4E, CYLD, BCL3, TNF, AKT2, CALM1, MAPK14 | More | |
Copanlisib | hsa04657 | IL-17 signaling pathway | 1.36E-02 | 5 | O00463, Q16539, P49841, P14780, P01375 | TRAF5, MAPK14, GSK3B, MMP9, TNF | More | |
Copanlisib | hsa04662 | B cell receptor signaling pathway | 1.60E-04 | 6 | P31751, P42338, P60033, P07948, P21854, Q8N149 | AKT2, PIK3CB, CD81, LYN, CD72, LILRA2 | More | |
Copanlisib | hsa04664 | Fc epsilon RI signaling pathway | 5.75E-04 | 7 | P01375, P31751, Q16539, P42338, Q9UQC2, P07948, P09917 | TNF, AKT2, MAPK14, PIK3CB, GAB2, LYN, ALOX5 | More | |
Copanlisib | hsa04668 | TNF signaling pathway | 2.21E-02 | 5 | P01375, O00463, Q16539, P20749, P14780 | TNF, TRAF5, MAPK14, BCL3, MMP9 | More | |
Copanlisib | hsa04720 | Long-term potentiation | 1.25E-03 | 6 | P17252, Q15418, P51812, P18848, P22694, Q02750 | PRKCA, RPS6KA1, RPS6KA3, ATF4, PRKACB, MAP2K1 | More | |
Copanlisib | hsa04722 | Neurotrophin signaling pathway | 2.83E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa04724 | Glutamatergic synapse | 5.94E-03 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | |
Copanlisib | hsa04725 | Cholinergic synapse | 2.59E-03 | 7 | P22694, P17252, P62879, P63218, P50151, P42338, Q02750 | PRKACB, PRKCA, GNB2, GNG5, GNG10, PIK3CB, MAP2K1 | More | |
Copanlisib | hsa04726 | Serotonergic synapse | 2.43E-02 | 4 | P22694, P17252, P62879, Q02750 | PRKACB, PRKCA, GNB2, MAP2K1 | More | |
Copanlisib | hsa04727 | GABAergic synapse | 1.08E-03 | 7 | P62879, P63218, P50151, P15104, P22694, O60296, P17252 | GNB2, GNG5, GNG10, GLUL, PRKACB, TRAK2, PRKCA | More | |
Copanlisib | hsa04728 | Dopaminergic synapse | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa04730 | Long-term depression | 3.52E-02 | 1 | Q14344 | GNA13 | More | |
Copanlisib | hsa04740 | Olfactory transduction | 2.41E-02 | 1 | P0DP23 | CALM1 | More | |
Copanlisib | hsa04744 | Phototransduction | 1.81E-02 | 1 | P0DP23 | CALM1 | More | |
Copanlisib | hsa04910 | Insulin signaling pathway | 9.82E-04 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | |
Copanlisib | hsa04915 | Estrogen signaling pathway | 5.07E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa04916 | Melanogenesis | 4.78E-02 | 1 | P0DP23 | CALM1 | More | |
Copanlisib | hsa04917 | Prolactin signaling pathway | 2.41E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa04918 | Thyroid hormone synthesis | 4.48E-02 | 2 | P18848, P05543 | ATF4, SERPINA7 | More | |
Copanlisib | hsa04919 | Thyroid hormone signaling pathway | 2.22E-02 | 5 | P17252, Q02750, P22694, Q12778, Q9UM47 | PRKCA, MAP2K1, PRKACB, FOXO1, NOTCH3 | More | |
Copanlisib | hsa04920 | Adipocytokine signaling pathway | 4.19E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa04922 | Glucagon signaling pathway | 1.79E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa04923 | Regulation of lipolysis in adipocytes | 3.01E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa04924 | Renin secretion | 3.01E-02 | 1 | P0DP23 | CALM1 | More | |
Copanlisib | hsa04926 | Relaxin signaling pathway | 5.70E-03 | 5 | P42338, P63218, P50151, P49767, P49407 | PIK3CB, GNG5, GNG10, VEGFC, ARRB1 | More | |
Copanlisib | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.48E-02 | 4 | P22694, Q02750, P17252, Q9Y5Q3 | PRKACB, MAP2K1, PRKCA, MAFB | More | |
Copanlisib | hsa04929 | GnRH secretion | 3.61E-03 | 3 | P42338, P31751, P49407 | PIK3CB, AKT2, ARRB1 | More | |
Copanlisib | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.38E-02 | 1 | P48048 | KCNJ1 | More | |
Copanlisib | hsa04970 | Salivary secretion | 9.00E-03 | 4 | P22694, P17252, P0DP23, P49913 | PRKACB, PRKCA, CALM1, CAMP | More | |
Copanlisib | hsa04971 | Gastric acid secretion | 4.78E-02 | 1 | P0DP23 | CALM1 | More | |
Copanlisib | hsa04973 | Carbohydrate digestion and absorption | 2.41E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa05010 | Alzheimer disease | 5.38E-04 | 7 | P13073, Q00535, P0DP23, P18848, P67870, P31751, P05141 | COX4I1, CDK5, CALM1, ATF4, CSNK2B, AKT2, SLC25A5 | More | |
Copanlisib | hsa05020 | Prion disease | 3.29E-02 | 4 | P13073, P18848, P05141, P67870 | COX4I1, ATF4, SLC25A5, CSNK2B | More | |
Copanlisib | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.60E-03 | 4 | Q06055, Q00535, O15020, P0DP23 | ATP5G2, CDK5, SPTBN2, CALM1 | More | |
Copanlisib | hsa05030 | Cocaine addiction | 4.19E-02 | 1 | Q00535 | CDK5 | More | |
Copanlisib | hsa05031 | Amphetamine addiction | 4.78E-02 | 1 | P0DP23 | CALM1 | More | |
Copanlisib | hsa05130 | Pathogenic Escherichia coli infection | 4.08E-02 | 3 | Q15438, P35579, P55061 | PSCD1, MYH9, TEGT | More | |
Copanlisib | hsa05152 | Tuberculosis | 9.92E-03 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | |
Copanlisib | hsa05163 | Human cytomegalovirus infection | 8.39E-03 | 8 | P31751, P01375, P0DP23, P49841, P14778, P25025, Q16539, O00463 | AKT2, TNF, CALM1, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | |
Copanlisib | hsa05165 | Human papillomavirus infection | 4.71E-03 | 10 | P46527, Q02750, P35443, Q92796, Q05086, Q9UM47, P22694, Q13362, Q12778, Q13315 | CDKN1B, MAP2K1, THBS4, DLG3, UBE3A, NOTCH3, PRKACB, PPP2R5C, FOXO1, ATM | More | |
Copanlisib | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 5.07E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa05169 | Epstein-Barr virus infection | 3.72E-02 | 6 | Q13547, P42338, P07948, Q13761, O75293, P07766 | HDAC1, PIK3CB, LYN, RUNX3, GADD45B, CD3E | More | |
Copanlisib | hsa05170 | Human immunodeficiency virus 1 infection | 6.71E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa05171 | Coronavirus disease - COVID-19 | 3.87E-04 | 5 | P62249, P40429, P27635, Q07020, P05386 | RPS16, RPL13A, RPL10, RPL18, RPLP1 | More | |
Copanlisib | hsa05200 | Pathways in cancer | 3.07E-02 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | |
Copanlisib | hsa05202 | Transcriptional misregulation in cancer | 3.76E-02 | 7 | Q12778, Q13315, Q15744, P46527, P05164, P08246, Q9C0K0 | FOXO1, ATM, CEBPE, CDKN1B, MPO, ELA2, BCL11B | More | |
Copanlisib | hsa05204 | Chemical carcinogenesis | 4.00E-02 | 1 | P09211 | GSTP1 | More | |
Copanlisib | hsa05206 | MicroRNAs in cancer | 3.66E-02 | 6 | P46527, Q9UM47, P16070, Q13315, P17252, Q02750 | CDKN1B, NOTCH3, CD44, ATM, PRKCA, MAP2K1 | More | |
Copanlisib | hsa05211 | Renal cell carcinoma | 4.78E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa05212 | Pancreatic cancer | 4.78E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa05213 | Endometrial cancer | 3.60E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa05214 | Glioma | 5.75E-04 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | |
Copanlisib | hsa05218 | Melanoma | 3.01E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa05220 | Chronic myeloid leukemia | 4.19E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa05221 | Acute myeloid leukemia | 4.19E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa05222 | Small cell lung cancer | 4.78E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa05223 | Non-small cell lung cancer | 2.41E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa05225 | Hepatocellular carcinoma | 1.85E-02 | 2 | Q92529, P51531 | SHC3, SMARCA2 | More | |
Copanlisib | hsa05226 | Gastric cancer | 3.60E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa05230 | Central carbon metabolism in cancer | 4.78E-02 | 1 | P31751 | AKT2 | More | |
Copanlisib | hsa05418 | Fluid shear stress and atherosclerosis | 6.43E-05 | 9 | Q16539, P31751, Q14145, P10599, P14780, P01375, P14778, P27930, P0DP23 | MAPK14, AKT2, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2, CALM1 | More | |